A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer.

Inclusion Criteria

Must have histological or cytological confirmed diagnosis of locally advanced or metastatic adenocarcinoma of the pancreas, which has progressed on or after one line of chemotherapy
ECOG Performance status 0-1
Adequate organ functions
Measurable disease

Exclusion Criteria

Suspected or known CNS metastasis
Participants with active, known, or suspected autoimmune disease
Uncontrolled or significant cardiovascular disease
Prior exposure to selected immune cell-modulating antibody regimens

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03336216.

State:

United States

Maryland

Baltimore

Johns Hopkins University/Sidney Kimmel Cancer Center

Status: Active

Name Not Available

Pennsylvania

Pittsburgh

University of Pittsburgh Cancer Institute (UPCI)

Status: Active

Name Not Available

Trial PhasePhase II

Trial Typetreatment

Lead OrganizationBristol-Myers Squibb

Primary IDCA025-006
Secondary IDsNCI-2017-02426
ClinicalTrials.gov IDNCT03336216

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Inclusion Criteria

Exclusion Criteria

United States

Maryland

Baltimore

Pennsylvania

Pittsburgh

Have a question?
We're here to help

Which trials are right for you?

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Description

Eligibility Criteria

Locations & Contacts

Trial Objectives and Outline

Trial Phase & Type

Lead Organization

Trial IDs

Have a question?We're here to help

Which trials are right for you?

Have a question?
We're here to help